McKnight's Long-Term Care News30m
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Weight Loss Drug Mounjaro to Be Launched in India in 2025; Know How It Tackles Obesity
Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...
The Spokesman-Review9h
FDA approves weight-loss drug Zepbound to treat sleep apnea
The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?
The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in ...
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
WQOW23h
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...